Jinbo Liu1, Peter J Mazzone2, Juan P Cata3, Andrea Kurz4, Maria Bauer4, Edward J Mascha5, Daniel I Sessler6. 1. Department of Outcomes Research, Department of Pulmonary, Allergy, Cleveland Clinic, Cleveland, OH; Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH. 2. Critical Care Medicine, Cleveland Clinic, Cleveland, OH. 3. Department of Outcomes Research, Department of Pulmonary, Allergy, Cleveland Clinic, Cleveland, OH; Department of Anesthesiology and Perioperative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX. 4. Department of Outcomes Research, Department of Pulmonary, Allergy, Cleveland Clinic, Cleveland, OH. 5. Department of Outcomes Research, Department of Pulmonary, Allergy, Cleveland Clinic, Cleveland, OH; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH. 6. Department of Outcomes Research, Department of Pulmonary, Allergy, Cleveland Clinic, Cleveland, OH. Electronic address: DS@OR.org.
Abstract
BACKGROUND: Lung cancer is the leading cause of cancer-related mortality. Surgical removal of the tumor at an early stage can be curative. However, lung cancer diagnosis at an early stage remains challenging. There is evidence that free fatty acids play a role in cancer development. METHODS: Serum samples from 55 patients with lung cancer were propensity matched with samples from 165 similar pulmonary patients without known cancer. Patients were propensity matched on age, sex, smoking history, family history of lung cancer, and chronic diseases that might affect free fatty acid levels. RESULTS: Free fatty acids arachidonic acid (AA) and linoleic acid (LA) and their metabolites hydroxyeicosatetraenoic acids (HETEs)(5-HETE, 11-HETE, 12-HETE, and 15-HETE) were an estimated 1.8- to 3.3-fold greater in 37 patients with adenocarcinoma vs 111 patients without cancer (all P < .001). Areas under the receiver operating characteristic curve were significantly > 0.50, discriminating patients with lung cancer and control subjects for six of eight biomarkers and two of seven phospholipids tested, and ranged between 0.69 and 0.82 (all P < .001) for patients with lung cancer vs control subjects. AA, LA, and 15-HETE had observed sensitivity and specificity > 0.70 at the best cutpoint. Concentrations of free fatty acids and their metabolites were similar in 18 patients with squamous cell carcinoma and 54 control subjects without cancer. CONCLUSIONS: Serum fatty acids and their metabolites demonstrate good sensitivity and specificity for the identification of adenocarcinoma of the lung.
BACKGROUND:Lung cancer is the leading cause of cancer-related mortality. Surgical removal of the tumor at an early stage can be curative. However, lung cancer diagnosis at an early stage remains challenging. There is evidence that free fatty acids play a role in cancer development. METHODS: Serum samples from 55 patients with lung cancer were propensity matched with samples from 165 similar pulmonary patients without known cancer. Patients were propensity matched on age, sex, smoking history, family history of lung cancer, and chronic diseases that might affect free fatty acid levels. RESULTS:Free fatty acidsarachidonic acid (AA) and linoleic acid (LA) and their metabolites hydroxyeicosatetraenoic acids (HETEs)(5-HETE, 11-HETE, 12-HETE, and 15-HETE) were an estimated 1.8- to 3.3-fold greater in 37 patients with adenocarcinoma vs 111 patients without cancer (all P < .001). Areas under the receiver operating characteristic curve were significantly > 0.50, discriminating patients with lung cancer and control subjects for six of eight biomarkers and two of seven phospholipids tested, and ranged between 0.69 and 0.82 (all P < .001) for patients with lung cancer vs control subjects. AA, LA, and 15-HETE had observed sensitivity and specificity > 0.70 at the best cutpoint. Concentrations of free fatty acids and their metabolites were similar in 18 patients with squamous cell carcinoma and 54 control subjects without cancer. CONCLUSIONS: Serum fatty acids and their metabolites demonstrate good sensitivity and specificity for the identification of adenocarcinoma of the lung.
Authors: Jieyun Yin; Hongliang Liu; Zhensheng Liu; Kouros Owzar; Younghun Han; Li Su; Yongyue Wei; Rayjean J Hung; Yonathan Brhane; John McLaughlin; Paul Brennan; Heike Bickeboeller; Albert Rosenberger; Richard S Houlston; Neil Caporaso; Maria Teresa Landi; Joachim Heinrich; Angela Risch; David C Christiani; Christopher I Amos; Qingyi Wei Journal: Mol Carcinog Date: 2017-02-23 Impact factor: 4.784
Authors: Pelin Cengiz; Frank Zemlan; Jens C Eickhoff; Richard Ellenbogen; Jerry J Zimmerman Journal: Childs Nerv Syst Date: 2015-04-22 Impact factor: 1.475
Authors: Sonia S Anand; Corinna Hawkes; Russell J de Souza; Andrew Mente; Mahshid Dehghan; Rachel Nugent; Michael A Zulyniak; Tony Weis; Adam M Bernstein; Ronald M Krauss; Daan Kromhout; David J A Jenkins; Vasanti Malik; Miguel A Martinez-Gonzalez; Dariush Mozaffarian; Salim Yusuf; Walter C Willett; Barry M Popkin Journal: J Am Coll Cardiol Date: 2015-10-06 Impact factor: 24.094
Authors: Tomasz Bodnarczuk; Anna Deskur; Katarzyna Dolegowska; Barbara Dolegowska; Teresa Starzynska; Wojciech Blogowski Journal: Am J Cancer Res Date: 2018-09-01 Impact factor: 6.166
Authors: Sonia T Anand; Kelli K Ryckman; Rebecca J Baer; Mary E Charlton; Patrick J Breheny; William W Terry; Kord Kober; Scott Oltman; Elizabeth E Rogers; Laura L Jelliffe-Pawlowski; Elizabeth A Chrischilles Journal: J Matern Fetal Neonatal Med Date: 2021-05-12
Authors: John S Kim; Brian T Steffen; Anna J Podolanczuk; Steven M Kawut; Imre Noth; Ganesh Raghu; Erin D Michos; Eric A Hoffman; Gisli Thor Axelsson; Gunnar Gudmundsson; Vilmundur Gudnason; Elias F Gudmundsson; Rachel A Murphy; Josée Dupuis; Hanfei Xu; Ramachandran S Vasan; George T O'Connor; William S Harris; Gary M Hunninghake; R Graham Barr; Michael Y Tsai; David J Lederer Journal: Am J Epidemiol Date: 2021-01-04 Impact factor: 4.897